Unnamed: 0 int64 0 350k | level_0 int64 0 351k | ApplicationNumber int64 9.75M 96.1M | ArtUnit int64 1.6k 3.99k | Abstract stringlengths 1 8.37k | Claims stringlengths 3 292k | abstract-claims stringlengths 68 293k | TechCenter int64 1.6k 3.9k |
|---|---|---|---|---|---|---|---|
0 | 0 | 15,193,214 | 1,611 | The invention relates to liquid compositions for use with hair removal devices comprising a silicone polyether block copolymer comprising from 1% to 50%, by weight of polyethylene oxide, from 20% to 90% by weight of polypropylene oxide and from 1% to 20%, by weight of silicone for improved lubrication. | 1. A composition dispensing hair removal device, said device comprising a composition comprising from about 0.1% to about 60% by weight of a silicone polyether block copolymer wherein said silicone polyether block copolymer comprises from about 1 to about 50%, by weight of polyethylene oxide, from about 20% to about 90... | The invention relates to liquid compositions for use with hair removal devices comprising a silicone polyether block copolymer comprising from 1% to 50%, by weight of polyethylene oxide, from 20% to 90% by weight of polypropylene oxide and from 1% to 20%, by weight of silicone for improved lubrication.1. A composition ... | 1,600 |
1 | 1 | 14,553,869 | 1,633 | A method for in vivo, ex vivo and in vitro regeneration of cartilage and collagen. In vivo, ex vivo and in vitro regeneration and de novo formation of articular cartilage and collagen by intermittently applied hydrostatic pressure. The application of external interval loading consisting of repeated periods of applied h... | 1. A method of treating diseased, aged or injured osteoarthritic cartilage using pressure treated chondrocytes, said chondrocytes releasing a lowered level, when compared to non-treated osteoarthritic chondrocytes, of at least one protein selected from the group consisting of:
(i) matrix metalloproteinase-2 (MMP-2); (i... | A method for in vivo, ex vivo and in vitro regeneration of cartilage and collagen. In vivo, ex vivo and in vitro regeneration and de novo formation of articular cartilage and collagen by intermittently applied hydrostatic pressure. The application of external interval loading consisting of repeated periods of applied h... | 1,600 |
2 | 2 | 13,575,904 | 1,644 | Methods and compositions are provided for the treatment and diagnosis of diseases related to hyperglycemic conditions, including diabetes, insulin resistance, and the like. Genetic polymorphisms are shown to be associated with disease susceptibility, and their detection is used in the diagnosis of a predisposition to t... | 1. A method of treating or preventing the onset of type 2 diabetes in an individual, the method comprising:
administering to said individual an inhibitor of CD44. 2. The method of claim 1, wherein the CD44 is expressed on adipose tissue macrophages or adipocytes. 3. The method of claim 1, wherein said inhibitor inhibit... | Methods and compositions are provided for the treatment and diagnosis of diseases related to hyperglycemic conditions, including diabetes, insulin resistance, and the like. Genetic polymorphisms are shown to be associated with disease susceptibility, and their detection is used in the diagnosis of a predisposition to t... | 1,600 |
3 | 3 | 14,787,941 | 1,654 | The present invention for the first time discloses a novel small molecular weight enamel matrix polypeptide which is at least 80%, such as 90% identical to the amino acid sequence as shown in SEQ ID NO: 1 (MPLPPHPGHP GYINFSYEVL TPLKWYQNMI RHPYTSYGYE PMGGWLHHQI IPWSQQTPQ SHA) (TRAP63), a homologue, analogue, or a pharma... | 1. An enamel matrix polypeptide which is at least 80%, such ac 90% identical to the amino acid sequence as shown in SEQ ID NO: 1 (TRAP63), a homologue, analogue, or a pharmaceutically acceptable salt thereof, and which stimulates the tissue formation phase of a wound healing process. 2. A pharmaceutical composition com... | The present invention for the first time discloses a novel small molecular weight enamel matrix polypeptide which is at least 80%, such as 90% identical to the amino acid sequence as shown in SEQ ID NO: 1 (MPLPPHPGHP GYINFSYEVL TPLKWYQNMI RHPYTSYGYE PMGGWLHHQI IPWSQQTPQ SHA) (TRAP63), a homologue, analogue, or a pharma... | 1,600 |
4 | 4 | 15,167,507 | 1,631 | The present invention relates to methods for evaluating and/or predicting the outcome of a clinical condition, such as cancer, metastasis, AIDS, autism, Alzheimer's, and/or Parkinson's disorder. The methods can also be used to monitor and track changes in a patient's DNA and/or RNA during and following a clinical treat... | 1. A computer-based genomic sequence analysis system comprising:
a memory storing at least two genomic sequence datasets including:
a tumor sequence dataset comprising genomic sequence strings of a tumor tissue sample of a patient; and
a matched normal dataset comprising genomic sequence strings of a normal tissue samp... | The present invention relates to methods for evaluating and/or predicting the outcome of a clinical condition, such as cancer, metastasis, AIDS, autism, Alzheimer's, and/or Parkinson's disorder. The methods can also be used to monitor and track changes in a patient's DNA and/or RNA during and following a clinical treat... | 1,600 |
5 | 5 | 14,367,610 | 1,652 | The present invention relates to a microorganism having a reduced fatty acid degradation capacity and expressing a recombinant alkane oxidase, a method for oxidizing an alkyl, comprising a contacting the alkyl with an aqueous solution comprising the inventive cell. | 1. A microorganism having a reduced fatty acid degradation capacity and expressing a recombinant alkane oxidase. 2. The microorganism according to claim 1, wherein the expressed recombinant alkane oxidase is selected from the group consisting of a rubredoxin-dependent alkane oxidase, a cytochrome P450 enzyme, a xylene ... | The present invention relates to a microorganism having a reduced fatty acid degradation capacity and expressing a recombinant alkane oxidase, a method for oxidizing an alkyl, comprising a contacting the alkyl with an aqueous solution comprising the inventive cell.1. A microorganism having a reduced fatty acid degradat... | 1,600 |
6 | 6 | 12,262,834 | 1,616 | Compositions containing one or more metal phosphites and prohexadione calcium are suitable for providing micronutrients for plant health and growth regulation when applied to agricultural crops. | 1. A method of treating agricultural crops, comprising:
applying a composition to a crop, wherein the composition comprises prohexadione calcium and one or more metal phosphites in aqueous solution; wherein the one or more metal phosphites are selected from the group consisting of zinc phosphite, manganese phosphite, m... | Compositions containing one or more metal phosphites and prohexadione calcium are suitable for providing micronutrients for plant health and growth regulation when applied to agricultural crops.1. A method of treating agricultural crops, comprising:
applying a composition to a crop, wherein the composition comprises pr... | 1,600 |
7 | 7 | 15,559,054 | 1,637 | A composition for detecting hepatitis B virus cccDNA includes an upstream primer having the DNA sequence set forth in SEQ ID NO. 1, a downstream primer having the DNA sequence set forth in SEQ ID NO. 2, and a TaqMan probe having the DNA sequence set forth in SEQ ID NO. 3. A qualitative and absolute quantification kit f... | 1. A composition for detecting hepatitis B virus cccDNA, comprising an upstream primer having the DNA sequence set forth in SEQ ID NO. 1, a downstream primer having the DNA sequence set forth in SEQ ID NO. 2, and a TaqMan probe having the DNA sequence set forth in SEQ ID NO. 3. 2. A qualitative and absolute quantificat... | A composition for detecting hepatitis B virus cccDNA includes an upstream primer having the DNA sequence set forth in SEQ ID NO. 1, a downstream primer having the DNA sequence set forth in SEQ ID NO. 2, and a TaqMan probe having the DNA sequence set forth in SEQ ID NO. 3. A qualitative and absolute quantification kit f... | 1,600 |
8 | 8 | 13,111,105 | 1,653 | The disclosure provides an oral composition for reducing serum cholesterol, serum lipids, body fat, or atherogenic index or for prophylaxis or treatment of atherosclerosis, cardiovascular or cerebrovascular diseases, comprising a highly bsh active bacteria, isolate or supernatant thereof; wherein the highly bsh active ... | 1. An oral composition comprising a highly bsh active bacteria, isolate or supernatant thereof; wherein the highly bsh active bacteria degrades >50 μmol GDCA/gram/hour and >2 μmol TDCA/gram/hour when measured over 1 hour and 5 hours, respectively; or >65 μmol GDCA/g/hr and >7 μmol TDCA/g/hr when measured over 30 minute... | The disclosure provides an oral composition for reducing serum cholesterol, serum lipids, body fat, or atherogenic index or for prophylaxis or treatment of atherosclerosis, cardiovascular or cerebrovascular diseases, comprising a highly bsh active bacteria, isolate or supernatant thereof; wherein the highly bsh active ... | 1,600 |
9 | 9 | 13,175,566 | 1,648 | We describe herein a cell-based multiplexing technique called detectable cell barcoding (DCB). In DCB, each individual sample is labeled with a different DCB signature that distinguishes each sample by one or both of detected intensity or type of detection characteristic. The samples are then combined and analyzed for ... | 1-21. (canceled) 22. A kit comprising at least one detectable cell barcode (DCB) label in a form that is optimized to DCB label multiple cell samples according the method of claim 1, wherein said at least one DCB label is pre-measured into aliquots, wherein each of said aliquots comprises a different amount of said at ... | We describe herein a cell-based multiplexing technique called detectable cell barcoding (DCB). In DCB, each individual sample is labeled with a different DCB signature that distinguishes each sample by one or both of detected intensity or type of detection characteristic. The samples are then combined and analyzed for ... | 1,600 |
10 | 10 | 13,000,667 | 1,631 | An olfaction processor (OLP) ( 100 ) that generates RAW data ( 35 ) including content data ( 139 d ) relating to chemical substances is provided. The OLP ( 100 ) includes a generator ( 130 ) that generates the RAW data ( 35 ). The chemical substances include at least one of compounds, molecules, and elements. The gen... | 1. A system including a generator that generates first data including content data relating to chemical substances,
wherein the chemical substances include at least one of compounds, molecules, and elements, and the generator comprises a conversion unit that converts intensity variations showing detected chemical subst... | An olfaction processor (OLP) ( 100 ) that generates RAW data ( 35 ) including content data ( 139 d ) relating to chemical substances is provided. The OLP ( 100 ) includes a generator ( 130 ) that generates the RAW data ( 35 ). The chemical substances include at least one of compounds, molecules, and elements. The gen... | 1,600 |
11 | 11 | 13,765,577 | 1,653 | Semen and sperm cell processing and preservation systems, and methods of producing a mammal and methods of producing mammalian embryos are disclosed. The present invention is directed to sperm cell preservation, fertilization, and insemination, maintaining or enhancing sperm quality and addressing one or more sperm cel... | 1-53. (canceled) 54. A method of producing a non-human mammalian embryo comprising:
obtaining cryopreserved sperm cells; thawing the cryopreserved sperm cells; sorting the thawed sperm cells; cryopreserving the sorted sperm cells; thawing the twice cryopreserved sperm cells; fertilizing at least one egg with the thawed... | Semen and sperm cell processing and preservation systems, and methods of producing a mammal and methods of producing mammalian embryos are disclosed. The present invention is directed to sperm cell preservation, fertilization, and insemination, maintaining or enhancing sperm quality and addressing one or more sperm cel... | 1,600 |
12 | 12 | 13,932,051 | 1,633 | Compositions and methods for reducing susceptibility to infectious disease in bees using RNA interference technology, and more particularly, prevention and treatment of viral infections in honeybees such as Israel acute paralysis virus (IAPV) by feeding of pathogen-specific dsRNA. Further, multiple-pathogen specific ds... | 1. A method for increasing the tolerance of a honeybee to a disease caused by a bee pathogen, comprising feeding the bee an effective amount of a bee-ingestible composition comprising a double stranded ribonucleic acid (dsRNA) comprising an RNA sequence capable of hybridizing to an mRNA transcript encoding a polypeptid... | Compositions and methods for reducing susceptibility to infectious disease in bees using RNA interference technology, and more particularly, prevention and treatment of viral infections in honeybees such as Israel acute paralysis virus (IAPV) by feeding of pathogen-specific dsRNA. Further, multiple-pathogen specific ds... | 1,600 |
13 | 13 | 13,462,375 | 1,628 | Novel compositions including bepotastine besilate are provided such as sorbitol-free compositions, compositions including at least about 0.008% w/v benzalkonium chloride, and compositions including hydroxypropylmethyl cellulose E15 LV. | 1-58. (canceled) 59. A method of treating at least one of rhinitis, mucosal inflammation associated with rhinitis, sinusitis, rhinosinusitis, and symptoms associated with rhinitis, mucosal inflammation associated with rhinitis, sinusitis, and/or rhinosinusitis in a patient in need of such treatment, the method comprisi... | Novel compositions including bepotastine besilate are provided such as sorbitol-free compositions, compositions including at least about 0.008% w/v benzalkonium chloride, and compositions including hydroxypropylmethyl cellulose E15 LV.1-58. (canceled) 59. A method of treating at least one of rhinitis, mucosal inflammat... | 1,600 |
14 | 14 | 14,471,825 | 1,631 | A tag database establishment section converts, based on information such as an amino acid sequence of an identified peptide and m/z of a peak, a sequence tag indicating a partial sequence and information related to the tag into a database and creates a tag database. When MS2 spectrum information is obtained by measurin... | 1. A mass spectrometric data analyzing apparatus that identifies, based on MSn spectrum data collected by executing an MSn analysis (n is an integer equal to or larger than 2) on a test sample, a target peptide in the test sample, the mass spectrometric data analyzing apparatus comprising:
a) a tag database establishme... | A tag database establishment section converts, based on information such as an amino acid sequence of an identified peptide and m/z of a peak, a sequence tag indicating a partial sequence and information related to the tag into a database and creates a tag database. When MS2 spectrum information is obtained by measurin... | 1,600 |
15 | 15 | 12,994,031 | 1,612 | The present invention provides liposomes that are useful for delivery of bioactive agents such as therapeutics. Among others, the liposomes of the invention are capable of delivering their payload at sites of increased secretory phospholipase A2 (sPLA2) activity, because phospholipase A2 (PLA2) will hydrolyse lipids of... | 1. A liposome comprising
between 25% and 45% (mol/mol) of an anionic lipid, less than 1% cholesterol (mol/mol) and a therapeutic agent selected from the group consisting of small molecule antitumour agents, antibiotics, antifungals, and anti-inflammatory agents
wherein the liposome has been exposed to a divalent cation... | The present invention provides liposomes that are useful for delivery of bioactive agents such as therapeutics. Among others, the liposomes of the invention are capable of delivering their payload at sites of increased secretory phospholipase A2 (sPLA2) activity, because phospholipase A2 (PLA2) will hydrolyse lipids of... | 1,600 |
16 | 16 | 14,412,176 | 1,616 | The invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and a milk thistle extract or powder. The invention also relates to the combination of a sulforaphane or a derivative thereof and a milk thistle extrac... | 1-14. (canceled) 15. An orally administrable composition comprising a broccoli extract or powder and a milk thistle extract or powder. 16. The orally administrable composition of claim 15, wherein the broccoli extract or powder comprises glucoraphanin in an amount of about 1 to about 75% w/w. 17. The orally administrab... | The invention relates to the combination of a sulforaphane precursor, an enzyme capable of converting the sulforaphane precursor to sulforaphane, an enzyme potentiator, and a milk thistle extract or powder. The invention also relates to the combination of a sulforaphane or a derivative thereof and a milk thistle extrac... | 1,600 |
17 | 17 | 12,681,814 | 1,699 | The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides vaccine nanocarriers capable of stimulating an immune response in T cells and/or in B cells, in some embodiments, comprising at least one immunomodulatory agent, and optionally comp... | 1-386. (canceled) 387. Nanoparticles formed of polymer or lipid having a diameter of between 40 nm and 400 nm,
having incorporated therein T cell antigens, the nanoparticles having bound to or present on the surface B cell antigen, preferably in a density activating B cell receptors, and/or having immunomodulatory agen... | The present invention provides compositions and systems for delivery of nanocarriers to cells of the immune system. The invention provides vaccine nanocarriers capable of stimulating an immune response in T cells and/or in B cells, in some embodiments, comprising at least one immunomodulatory agent, and optionally comp... | 1,600 |
18 | 18 | 12,741,030 | 1,651 | The present invention provides a method for providing alpha-1 antitrypsin (α1-AT) to a subject, in particular a method for treating or preventing a disorder or disease associated with α1-AT deficiency in the subject, wherein the method comprises providing, subcutaneously, a therapeutically or prophylactically effective... | 1. A method for treating or preventing a disorder or disease associated with α1-AT deficiency in a subject, the method comprising administering, subcutaneously, a therapeutically or prophylactically effective amount of α1-AT to the subject. 2. A method for treating or preventing a disorder or disease associated with α1... | The present invention provides a method for providing alpha-1 antitrypsin (α1-AT) to a subject, in particular a method for treating or preventing a disorder or disease associated with α1-AT deficiency in the subject, wherein the method comprises providing, subcutaneously, a therapeutically or prophylactically effective... | 1,600 |
19 | 19 | 14,659,318 | 1,628 | Provided herein are steroid containing compositions suitable for providing therapeutically effective amounts of at least one steroid to individuals. Also provided herein are compositions comprising testosterone and/or testosterone derivatives suitable for providing therapeutically effective and safe amounts of testoste... | 1. A pharmaceutical composition comprising (i) a therapeutically effective amount of one or more testosterone C2-C13 alkyl ester; and (ii) at least one pharmaceutically acceptable carrier; the pharmaceutical composition releasing about 80% or less of the testosterone C2-C13 alkyl ester after 30 minutes in an aqueous me... | Provided herein are steroid containing compositions suitable for providing therapeutically effective amounts of at least one steroid to individuals. Also provided herein are compositions comprising testosterone and/or testosterone derivatives suitable for providing therapeutically effective and safe amounts of testoste... | 1,600 |
20 | 20 | 14,982,269 | 1,627 | The present invention relates to a mixture comprising (i) one or a plurality of 1,2-alkane diols with 5 through 8 carbon atoms and (ii) one or a plurality of ammonium-, sodium- or potassium-R alk -sarcosinates, wherein the structural element R alk represents alkanoyl, alkenoyl or alkadienoyl with 12 through 22 carbon ... | 1-21. (canceled) 22. A method of
increasing the solubility of pane or a plurality of organic substances, decreasing the turbidity of a preparation containing one or a plurality f organic substances, increasing the transparency of a preparation containing one or a plurality of organic, substances, wherein the organic su... | The present invention relates to a mixture comprising (i) one or a plurality of 1,2-alkane diols with 5 through 8 carbon atoms and (ii) one or a plurality of ammonium-, sodium- or potassium-R alk -sarcosinates, wherein the structural element R alk represents alkanoyl, alkenoyl or alkadienoyl with 12 through 22 carbon ... | 1,600 |
21 | 21 | 10,578,735 | 1,613 | The present invention relates to stable emulsifiable concentrates comprising an oil adjuvant and at least one member selected from the group consisting of herbicidally active 2-[4[(5-chloro-3-fluoropyridin-2-yloxy)-phenoxy]-propionic acid derivatives and quinoline derivative safeners and to the use thereof as a pestici... | 1. An emulsifiable concentrate comprising:
a) a herbicidally effective amount, preferably 1 to 30% by weight, of at least one herbicide; b) optionally, an amount, which is effective for antagonism of a herbicide, of at least one safener; c) 5 to 80%, preferably 25 to 70%, by weight of at least one oil adjuvant, wherein... | The present invention relates to stable emulsifiable concentrates comprising an oil adjuvant and at least one member selected from the group consisting of herbicidally active 2-[4[(5-chloro-3-fluoropyridin-2-yloxy)-phenoxy]-propionic acid derivatives and quinoline derivative safeners and to the use thereof as a pestici... | 1,600 |
22 | 22 | 14,509,809 | 1,643 | Methods of administering immunoconjugates that bind to FOLR1 are provided. The methods comprise administering an anti-FOLR1 immunoconjugate to a person in need thereof, for example, a cancer patient, at a therapeutically effective dosing regimen that results in minimal adverse effects. | 1. A method for treating a human patient having an FOLR1-expressing cancer comprising administering to the patient an immunoconjugate which binds to FOLR1 polypeptide, wherein the immunoconjugate is administered at a dose of about 3.0 to about 7 milligrams (mg) per kilogram (kg) of body weight of the patient, wherein t... | Methods of administering immunoconjugates that bind to FOLR1 are provided. The methods comprise administering an anti-FOLR1 immunoconjugate to a person in need thereof, for example, a cancer patient, at a therapeutically effective dosing regimen that results in minimal adverse effects.1. A method for treating a human p... | 1,600 |
23 | 23 | 15,846,944 | 1,612 | A whitening dentifrice composition, free from peroxide whitening agents, includes a blue coloring agent, a zinc core shell silica (Zn-CSS) particle, and an orally acceptable vehicle including a non-aqueous solvent and water. The blue coloring agent includes at least one of a blue pigment and a blue dye and has a blue t... | 1. A whitening dentifrice composition comprising:
a blue coloring agent comprising at least one of a blue pigment and a blue dye, wherein the blue coloring agent has a blue to blue-violet color with a hue angle in the CIELAB system ranging from 200 degrees to 320 degrees; a zinc core shell silica (Zn-CSS) particle, whe... | A whitening dentifrice composition, free from peroxide whitening agents, includes a blue coloring agent, a zinc core shell silica (Zn-CSS) particle, and an orally acceptable vehicle including a non-aqueous solvent and water. The blue coloring agent includes at least one of a blue pigment and a blue dye and has a blue t... | 1,600 |
24 | 24 | 12,462,404 | 1,631 | Systems and methods are described relating to accepting an indication of a schedule for administration of a memory-dampening agent to an individual and presenting an indication of an artificial sensory experience at least partly based on the accepting an indication of the schedule for administration of the memory-dampe... | 1-76. (canceled) 77. A system, comprising:
an accepter module; and a presenter module configured for presenting an indication of an artificial sensory experience at least partly based on accepting an indication of a schedule for administration of a memory-dampening agent to an individual. 78. The system of claim 77, wh... | Systems and methods are described relating to accepting an indication of a schedule for administration of a memory-dampening agent to an individual and presenting an indication of an artificial sensory experience at least partly based on the accepting an indication of the schedule for administration of the memory-dampe... | 1,600 |
25 | 25 | 12,517,906 | 1,662 | The subject invention relates to a novel gene referred to herein as DSM-2. This gene was identified in Sterptomyces coelicolor A3. The DSM-2 protein is distantly related to PAT and BAR. The subject invention also provides plant-optimized genes encoding DSM-2 proteins, DSM-2 can be used as a transgenic trait to impart... | 1. A transgenic plant cell comprising a polynucleotide that encodes a protein that has phosphinothricin acetyltransferase activity, wherein said polynucleotide hybridizes under conditions of 6×SSC at 65° C. with the full complement of a nucleic acid probe that encodes SEQ ID NO:2. 2. The cell of claim 1 wherein said pr... | The subject invention relates to a novel gene referred to herein as DSM-2. This gene was identified in Sterptomyces coelicolor A3. The DSM-2 protein is distantly related to PAT and BAR. The subject invention also provides plant-optimized genes encoding DSM-2 proteins, DSM-2 can be used as a transgenic trait to impart... | 1,600 |
26 | 26 | 14,654,063 | 1,653 | A process for producing oligosaccharides from lignocellulosic biomass, having the following steps:
a) pre-treating the biomass in a pre-treatment reactor ( 1 ) in order to provide an effluent containing a pre-treated substrate; b) enzymatic hydrolysis of the pre-treated substrate contained in the effluent fr... | 1. A process for the production of oligosaccharides from lignocellulosic biomass, comprising at least the following steps:
a) pre-treating the biomass in a pre-treatment reactor in order to provide an effluent containing a pre-treated substrate; b) carrying out an enzymatic hydrolysis of the pre-treated substrate conta... | A process for producing oligosaccharides from lignocellulosic biomass, having the following steps:
a) pre-treating the biomass in a pre-treatment reactor ( 1 ) in order to provide an effluent containing a pre-treated substrate; b) enzymatic hydrolysis of the pre-treated substrate contained in the effluent fr... | 1,600 |
27 | 27 | 14,768,465 | 1,635 | The presently disclosed subject matter provides a novel approach for the treatment, prevention, and diagnosis of Cap-Snatching virus infections, particularly all classes of human influenza, including pandemic influenza. The methods involve the use of constructs for RNA-interference (RNAi). | 1. An expression vector comprising a polynucleotide coding sequence operably linked to a constitutive promoter, wherein the polynucleotide coding sequence encodes a precursor RNAi construct, wherein the precursor RNAi construct comprises an mRNA molecule comprising:
(a) a 5′ methylguanosine cap leader; (b) an 8 to 12 n... | The presently disclosed subject matter provides a novel approach for the treatment, prevention, and diagnosis of Cap-Snatching virus infections, particularly all classes of human influenza, including pandemic influenza. The methods involve the use of constructs for RNA-interference (RNAi).1. An expression vector compri... | 1,600 |
28 | 28 | 14,897,459 | 1,631 | Methods and associated apparatus involving designing a ligand ab initio that will bind to a binding site of a macromolecular target, or of identifying a modification to a ligand for improving the affinity of the ligand to a binding site of a macromolecular target, comprising using information about non-bonding, intra-m... | 1. A method for designing a ligand ab initio that will bind to a binding site of a macromolecular target, or of identifying a modification to a ligand for improving the affinity of the ligand to a binding site of a macromolecular target, comprising:
a) identifying a target list of atoms forming the surface of the targe... | Methods and associated apparatus involving designing a ligand ab initio that will bind to a binding site of a macromolecular target, or of identifying a modification to a ligand for improving the affinity of the ligand to a binding site of a macromolecular target, comprising using information about non-bonding, intra-m... | 1,600 |
29 | 29 | 12,008,385 | 1,634 | The present invention provides a method for the isolation of sperm DNA from swabs taken from rape victims without having to perform a change in buffers. Non-sperm cells from the victim are digested with an enzyme and solubilized, and then in the same buffer an enzyme capable of digesting soluble DNA is added and the vi... | 1. A method for purifying sperm DNA from sexual assault samples comprising: a) obtaining a sample containing sperm cells and non-sperm cells, and placing these cells in a buffer compatible with enzymes that can digest non-sperm cells and soluble DNA, b) selectively degrading the non-sperm cells with an enzyme to obtain... | The present invention provides a method for the isolation of sperm DNA from swabs taken from rape victims without having to perform a change in buffers. Non-sperm cells from the victim are digested with an enzyme and solubilized, and then in the same buffer an enzyme capable of digesting soluble DNA is added and the vi... | 1,600 |
30 | 30 | 13,011,407 | 1,629 | The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and p... | 1-71. (canceled) 72. A compound according to formula (I):
or a salt or N-oxide thereof, wherein:
Q is selected from the group consisting of nitro and amino; and
two R35 bonded to the same carbon atom are taken together to form an oxo (═O) group and the other two R35 are each, independently of one another, sel... | The present invention provides 2,4-pyrimidinediamine compounds that inhibit the IgE and/or IgG receptor signaling cascades that lead to the release of chemical mediators, intermediates and methods of synthesizing the compounds and methods of using the compounds in a variety of contexts, including in the treatment and p... | 1,600 |
31 | 31 | 13,937,292 | 1,612 | The present invention relates generally to agents and devices for promoting hemostasis and tissue sealing and, more particularly, to hemostatic pads comprising bioabsorbable scaffolds that can deliver lyophilized hemostasis promoting proteins, such as fibrinogen and thrombin, to a wound site or injured organ or tissue. | 1. A hemostatic wound treatment device comprising:
a bioabsorbable scaffold having a wound facing surface and an opposing surface; said scaffold wetted with a biocompatible liquid that is not blood or plasma; and a hemostatic powder that adheres by moisture to at least the wound facing surface of said bioabsorbable sca... | The present invention relates generally to agents and devices for promoting hemostasis and tissue sealing and, more particularly, to hemostatic pads comprising bioabsorbable scaffolds that can deliver lyophilized hemostasis promoting proteins, such as fibrinogen and thrombin, to a wound site or injured organ or tissue.... | 1,600 |
32 | 32 | 11,958,827 | 1,651 | A microbe-specific medium, containing specific chromogenic substrates, for the detection of vancomycin-resistant enterococci in a biological sample, whereby both the detection and identification of vancomycin-resistant enterococci at the species level is achieved utilizing one sample and one test. | 1. A medium for identifying and distinguishing species of a microorganism placed in the medium comprising:
a first substrate conjugated to a first imaging moiety, wherein the first substrate is selected to interact preferentially with a first enzyme that is produced by a first species of microorganism compared to a sec... | A microbe-specific medium, containing specific chromogenic substrates, for the detection of vancomycin-resistant enterococci in a biological sample, whereby both the detection and identification of vancomycin-resistant enterococci at the species level is achieved utilizing one sample and one test.1. A medium for identi... | 1,600 |
33 | 33 | 15,919,361 | 1,627 | Administration of a salt of bi-cyclo [2.2.2] octane-2-carbonic acid reduces dysphoria in dysphoric subjects, ameliorates ethanol craving in alcoholics, reduces the erythrocyte sedimentation rate and the level of liver function markers (AST, ALT, and bilirubin) in human subjects, and reduces the number or strength of se... | 1. A method for reducing the number or strength of seizures in a human subject suffering from epilepsy, the method comprising the step of orally administering to the subject 50-1200 mg of the bicyclo-[2.2.2]-octane-2-carboxylate salt per day at least until the number or strength of seizures in a human subject is reduce... | Administration of a salt of bi-cyclo [2.2.2] octane-2-carbonic acid reduces dysphoria in dysphoric subjects, ameliorates ethanol craving in alcoholics, reduces the erythrocyte sedimentation rate and the level of liver function markers (AST, ALT, and bilirubin) in human subjects, and reduces the number or strength of se... | 1,600 |
34 | 34 | 15,934,595 | 1,612 | Orally administerable deferasirox formulations are disclosed having reduced release under gastric conditions and fast release at near neutral pH or at neutral pH. | 1-36. (canceled) 37. A method of treatment of chronic iron overload in a patient comprising directly orally administering 90 mg deferasirox or a pharmaceutically acceptable salt thereof in a solid swallowable dosage form wherein the dosage form is a whole and intact tablet. 38. A method of treatment of chronic iron ove... | Orally administerable deferasirox formulations are disclosed having reduced release under gastric conditions and fast release at near neutral pH or at neutral pH.1-36. (canceled) 37. A method of treatment of chronic iron overload in a patient comprising directly orally administering 90 mg deferasirox or a pharmaceutica... | 1,600 |
35 | 35 | 15,001,302 | 1,618 | The present disclosure provides a rapidly disintegrating orally administrable powder. The powder may include an active ingredient such as a dietary supplement. Methods of using the same are also provided herein. | 1. A composition comprising a powder including:
at least one bulking agent; at least one sweetening ingredient; and at least one active ingredient selected from the group consisting of Vitamin A, Vitamin C, Vitamin D, Vitamin E, Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, Chr... | The present disclosure provides a rapidly disintegrating orally administrable powder. The powder may include an active ingredient such as a dietary supplement. Methods of using the same are also provided herein.1. A composition comprising a powder including:
at least one bulking agent; at least one sweetening ingredien... | 1,600 |
36 | 36 | 12,949,420 | 1,631 | The present invention relates to methods for increasing the accuracy of sample classification characterized by the detection of the protein YKL-40 and the protein MASP2 in the samples and methods for determining the efficacy of a drug in treating a cancer in an individual, as well as reagent kits for the same uses. | 1. A method for increasing the accuracy of sample classification, characterized by the detection of the protein YKL-40 and the protein MASP2 in the samples. 2. The method according to claim 1, characterized in that the detection comprises:
(1) measuring the concentrations of YKL-40 and MASP2 in the samples; (2) algorit... | The present invention relates to methods for increasing the accuracy of sample classification characterized by the detection of the protein YKL-40 and the protein MASP2 in the samples and methods for determining the efficacy of a drug in treating a cancer in an individual, as well as reagent kits for the same uses.1. A... | 1,600 |
37 | 37 | 14,533,743 | 1,631 | Provided herein, among other things, is a computer-implemented method for assigning a sequence read to a genomic location, the method including: a) accessing a file containing a sequence read, wherein the sequence read is obtained from a nucleic acid sample that has been enriched by hybridization to a plurality of capt... | 1. A computer-implemented method for assigning a sequence read to a genomic location, comprising:
a) accessing a file comprising a sequence read, wherein the sequence read is obtained from a nucleic acid sample that has been enriched by hybridization to a plurality of capture sequences; and b) assigning the sequence re... | Provided herein, among other things, is a computer-implemented method for assigning a sequence read to a genomic location, the method including: a) accessing a file containing a sequence read, wherein the sequence read is obtained from a nucleic acid sample that has been enriched by hybridization to a plurality of capt... | 1,600 |
38 | 38 | 12,768,471 | 1,632 | The present invention relates to pluripotent stem cells, particularly to pluripotent embryonic-like stem cells. The invention further relates to methods of purifying pluripotent embryonic-like stem cells and to compositions, cultures and clones thereof. The present invention also relates to a method of transplanting th... | 1. A pluripotent embryonic-like stem cell, derived from non-embryonic or postnatal animal cells or tissue, capable of self-renewal and capable of differentiation to cells of endodermal, ectodermal and mesodermal lineages. 2. The stem cell of claim 1 which is a human cell. 3. (canceled) 4. (canceled) 5. (canceled) 6. (c... | The present invention relates to pluripotent stem cells, particularly to pluripotent embryonic-like stem cells. The invention further relates to methods of purifying pluripotent embryonic-like stem cells and to compositions, cultures and clones thereof. The present invention also relates to a method of transplanting th... | 1,600 |
39 | 39 | 15,394,085 | 1,648 | The present invention discloses positive control material for nucleic acid amplification based detection of microorganisms in biological samples. The control material comprises purified microorganism that is rendered non-infectious but is amenable to nucleic acid amplification. Also disclosed is a process for making an... | 1. A method for making a full process positive control material for detection of virus in biological samples comprising:
a) purifying an intact virus from a source; b) exposing the purified intact virus to an aldehyde at a temperature and for a time such that one or more surface proteins are irreversibly modified while... | The present invention discloses positive control material for nucleic acid amplification based detection of microorganisms in biological samples. The control material comprises purified microorganism that is rendered non-infectious but is amenable to nucleic acid amplification. Also disclosed is a process for making an... | 1,600 |
40 | 40 | 14,722,473 | 1,653 | Methods for reducing the occurrence or preventing formation of bladder calculi associated with bladder augmentation or bladder reconstruction. | 1. A method for reducing the occurrence of bladder calculi in a patient in need of a bladder augmentation or bladder reconstruction surgical procedure, the method comprising locally administering a composition comprising a therapeutically effective amount of a clostridial derivative to the patient. 2. The method of cla... | Methods for reducing the occurrence or preventing formation of bladder calculi associated with bladder augmentation or bladder reconstruction.1. A method for reducing the occurrence of bladder calculi in a patient in need of a bladder augmentation or bladder reconstruction surgical procedure, the method comprising loca... | 1,600 |
41 | 41 | 15,101,153 | 1,612 | Described herein are oral care compositions comprising a crosslinked polyvinylpyrrolidone complexed with hydrogen peroxide, together with a fatty amphiphile; including some embodiments which further comprise a calcium abrasive. | 1. A dentifrice composition comprising (i) a whitening complex comprising crosslinked polyvinylpyrrolidone complexed with hydrogen peroxide, (ii) a fatty amphiphile. 2. The composition of claim 1 wherein the fatty amphiphile is selected from fatty C12 to C28 alcohols or mixtures thereof. 3. The composition of claim 1 w... | Described herein are oral care compositions comprising a crosslinked polyvinylpyrrolidone complexed with hydrogen peroxide, together with a fatty amphiphile; including some embodiments which further comprise a calcium abrasive.1. A dentifrice composition comprising (i) a whitening complex comprising crosslinked polyvin... | 1,600 |
42 | 42 | 14,115,770 | 1,612 | The present invention provides, in part, cochleate compositions and methods for making and using same. | 1. A cochleate composition comprising a population of cochleates, wherein the cochleates comprise:
a) a negatively charged first lipid; b) a cation, wherein the cation is a divalent cation or a higher valency cation selected from the group consisting of calcium, zinc, barium, and magnesium cations; c) a second lipid; a... | The present invention provides, in part, cochleate compositions and methods for making and using same.1. A cochleate composition comprising a population of cochleates, wherein the cochleates comprise:
a) a negatively charged first lipid; b) a cation, wherein the cation is a divalent cation or a higher valency cation se... | 1,600 |
43 | 43 | 14,293,312 | 1,627 | Disclosed is a cosmetic or dermatological formulation comprising a) at least one polyol in a concentration of from 0.1 to 20% by weight, based on the total weight of the formulation, and b) at least one diol selected from 2-methyl-1,3-propanediol, pentanediol, and hexanediol, in a concentration of from 0.1 to 25% by we... | 1. A cosmetic or dermatological formulation, wherein the formulation comprises
(a) one or more of glycerol, propylene glycol, and butylene glycol in a total concentration of from 0.1% to 20% by weight, based on a total weight of the formulation, (b) 2-methyl-1,3-propanediol and, optionally, one or both of pentanediol a... | Disclosed is a cosmetic or dermatological formulation comprising a) at least one polyol in a concentration of from 0.1 to 20% by weight, based on the total weight of the formulation, and b) at least one diol selected from 2-methyl-1,3-propanediol, pentanediol, and hexanediol, in a concentration of from 0.1 to 25% by we... | 1,600 |
44 | 44 | 12,451,918 | 1,628 | A non-aqueous topical solution composition of pharmaceutically acceptable salt of diclofenac is disclosed. The non-aqueous topical solution composition comprises therapeutically effective amount of pharmaceutically acceptable salt of diclofenac, solublizer, penetration enhancer and solvent, and optionally a humectant, ... | 1. A novel composition of non-aqueous topical solution comprising:
an effective amount of pharmaceutically acceptable salt of diclofenac; about 10 to 30% v/v of lower chain alcohol as penetration enhancer and solublizer; a solvent selected from propylene glycol, glycofurol or their mixture thereof; and optionally a hum... | A non-aqueous topical solution composition of pharmaceutically acceptable salt of diclofenac is disclosed. The non-aqueous topical solution composition comprises therapeutically effective amount of pharmaceutically acceptable salt of diclofenac, solublizer, penetration enhancer and solvent, and optionally a humectant, ... | 1,600 |
45 | 45 | 15,054,899 | 1,618 | The invention pertains to dispersible tablets comprising as active ingredient 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid or pharmaceutically acceptable salt thereof in an amount of from 5 to 40% in weight by weight of the total tablet. | 1-15. (canceled) 16. A dispersible tablet comprising deferasirox or a pharmaceutically acceptable salt thereof in an amount selected from the group consisting of about 125 mg, about 250 mg, and about 500 mg, wherein the tablet exhibits a disintegration time of less than 5 minutes when measured by a standard USP disinte... | The invention pertains to dispersible tablets comprising as active ingredient 4-[3,5-bis(2-hydroxyphenyl)-[1,2,4]triazol-1-yl]benzoic acid or pharmaceutically acceptable salt thereof in an amount of from 5 to 40% in weight by weight of the total tablet.1-15. (canceled) 16. A dispersible tablet comprising deferasirox or... | 1,600 |
46 | 46 | 14,444,105 | 1,644 | We describe a particle secreted by a mesenchymal stem cell and comprising at least one biological property of a mesenchymal stem cell. The biological property may comprise a biological activity of a mesenchymal stem cell conditioned medium (MSC-CM) such as cardioprotection or reduction of infarct size. The particle may... | 1. A method of promoting wound healing, the method comprising administering to an individual in need thereof a pharmaceutical composition comprising an exosome derived from a mesenchymal stem cell (MSC). 2. The method of claim 1, in which the pharmaceutical composition comprises a pharmaceutically acceptable carrier. 3... | We describe a particle secreted by a mesenchymal stem cell and comprising at least one biological property of a mesenchymal stem cell. The biological property may comprise a biological activity of a mesenchymal stem cell conditioned medium (MSC-CM) such as cardioprotection or reduction of infarct size. The particle may... | 1,600 |
47 | 47 | 13,524,837 | 1,644 | New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise, in particular, administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkin's lymphomas. | 1. A method of extending median time to progression for responders by at least 13 months in patients with relapsed or refractory, low grade or follicular, CD20-positive, B-cell non-Hodgkin's lymphoma, comprising administering four doses of 375 mg/m2 of rituximab to the patients. 2. A method according to claim 1, wherei... | New combined therapeutic regimens for treatment of B-cell lymphomas are disclosed which comprise, in particular, administration of anti-CD20 antibodies to patients having low-, intermediate- or high-grade non-Hodgkin's lymphomas.1. A method of extending median time to progression for responders by at least 13 months in... | 1,600 |
48 | 48 | 15,131,485 | 1,612 | The present disclosure provides a liposome for delivering an extracellular matrix, a method for promoting cell growth, and a method for preparing a liposome for delivering an extracellular matrix. According to the present disclosure, the liposome for delivering an extracellular matrix promotes cell attachment and growt... | 1. A liposome for delivering an extracellular matrix, the liposome comprising:
(a) a phospholipid membrane having an anionic lipid and a neutral lipid, which are self-assembled; and (b) an extracellular matrix bound to the anionic lipid by ionic boding to be disposed on a surface of the anionic lipid. 2. The liposome o... | The present disclosure provides a liposome for delivering an extracellular matrix, a method for promoting cell growth, and a method for preparing a liposome for delivering an extracellular matrix. According to the present disclosure, the liposome for delivering an extracellular matrix promotes cell attachment and growt... | 1,600 |
49 | 49 | 14,307,231 | 1,627 | A method is provided for treating a subject in need of therapy for depression, anxiety, impaired cognition and/or pain comprising administering to said subject an amount of a ketogenic material sufficient to produce a ketosis in the subject sufficient to provide anti-depressant effect, cognition enhancing and/or analge... | 1-8. (canceled) 9. A method of treating a subject in need of therapy for depression and/or anxiety, comprising orally administering to said subject 5 to 5000 mg/kg body weight per day of a material selected from the group consisting of (R)-3-hydroxybutyrate, its salts, oligomers of (R)-3-hydroxybutyrate and esters of (... | A method is provided for treating a subject in need of therapy for depression, anxiety, impaired cognition and/or pain comprising administering to said subject an amount of a ketogenic material sufficient to produce a ketosis in the subject sufficient to provide anti-depressant effect, cognition enhancing and/or analge... | 1,600 |
50 | 50 | 14,315,039 | 1,633 | Model systems and methods for exploring mechanisms of carcinogenesis and the acquisition of metastatic ability, and to provide insights into potential therapeutic targets. The systems include and methods involve fusion of a stem cell and a genetically altered cell to evaluate carcinogenesis and metastasis and for the d... | 1. A composition comprising, an antibody against ubiquitin in a pharmaceutically acceptable carrier and one or more tumor cells. 2. The composition of claim 1, wherein said antibody against ubiquitin is present in an amount of between approximately 5 μg/ml/million tumor cells to 180 μg/ml/million tumor cells. 3. The co... | Model systems and methods for exploring mechanisms of carcinogenesis and the acquisition of metastatic ability, and to provide insights into potential therapeutic targets. The systems include and methods involve fusion of a stem cell and a genetically altered cell to evaluate carcinogenesis and metastasis and for the d... | 1,600 |
51 | 51 | 15,221,265 | 1,633 | A high-volume gene therapy vector manufacturing process which produces a recombinant gene therapy vector which is able to transform host cells even when they are not dividing. | 1. A method comprising:
a. Transducing a mammalian cell with a baculovirus to make a transduced mammalian producer cell; and then b. Culturing said transduced mammalian producer cell in culture media, and harvesting from said transduced mammalian producer cell and/or culture media a second virus having a therapeutic tr... | A high-volume gene therapy vector manufacturing process which produces a recombinant gene therapy vector which is able to transform host cells even when they are not dividing.1. A method comprising:
a. Transducing a mammalian cell with a baculovirus to make a transduced mammalian producer cell; and then b. Culturing sa... | 1,600 |
52 | 52 | 10,551,804 | 1,644 | The present invention refers to a novel combination of nucleotide and cellular vaccine composition and pharmaceutical composition and use thereof for treating and/or preventing diseases, including infectious diseases, cancer, autoimmune diseases, allergy, diabetes and blood disorders. The vaccine composition comprises ... | 1.-43. (canceled) 44. A nucleotide vaccine composition comprising a mixture of:
nucleotide sequence encoding an antigen; and antigen-presenting cells modified for expression of at least one of an immune response modulating molecule and a cell-survival modulating molecule. 45. The vaccine composition according to clai... | The present invention refers to a novel combination of nucleotide and cellular vaccine composition and pharmaceutical composition and use thereof for treating and/or preventing diseases, including infectious diseases, cancer, autoimmune diseases, allergy, diabetes and blood disorders. The vaccine composition comprises ... | 1,600 |
53 | 53 | 12,509,831 | 1,615 | The invention relates to an implant having a base body, consisting completely or partially of a biocorrodible metallic material, such that it decomposes in an aqueous environment to form an alkaline product, and the base body has a coating or a cavity filling, comprising a polymer matrix and at least one drug embedded ... | 1. An implant with a base body at least partially comprised of a biocorrodible metallic material, whereby the material is such that it decomposes in an aqueous environment to form an alkaline product and whereby the base body has one or more of a coating and a cavity filling comprising a polymer matrix and at least one... | The invention relates to an implant having a base body, consisting completely or partially of a biocorrodible metallic material, such that it decomposes in an aqueous environment to form an alkaline product, and the base body has a coating or a cavity filling, comprising a polymer matrix and at least one drug embedded ... | 1,600 |
54 | 54 | 15,460,872 | 1,642 | Described herein are methods, devices, and compositions for providing personalized medicine tests for hematological neoplasms. In some embodiments, the methods comprise measuring the efficacy of inducing apoptosis selectively in malignant cells using any number of potential alternative combination drug treatments. In s... | 1.-55. (canceled) 56. A method for analyzing cellular responsiveness to drugs, comprising:
a. obtaining a sample of whole blood, whole peripheral blood or whole bone marrow that has been withdrawn from a patient with a hematological neoplasm; b. dividing the whole sample into at least 35 aliquots; c. combining each of ... | Described herein are methods, devices, and compositions for providing personalized medicine tests for hematological neoplasms. In some embodiments, the methods comprise measuring the efficacy of inducing apoptosis selectively in malignant cells using any number of potential alternative combination drug treatments. In s... | 1,600 |
55 | 55 | 14,127,217 | 1,644 | The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a purine analog for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia. | 1. A synergistic combination of an antibody specific for CD19 comprising an antibody that cross-competes with an antibody comprising an HCDR1 region of sequence SYVMH (SEQ ID NO: 1), an HCDR2 region of sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of sequence R... | The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a purine analog for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.1. A synergistic combination of an antibody specific for CD19 comprising an antibody that cross-compete... | 1,600 |
56 | 56 | 15,872,516 | 1,624 | Compositions of matter that have antimicrobial properties and adhesion properties and are highly dispersible in aqueous solutions. The presence of a large number of silanols on the molecules of this invention creates a solubility or disperseability of these molecules in aqueous solutions that is not obtainable from pri... | 1-10. (canceled) 11. A method of reducing the number of bacteria, viruses, algae, mildew or mold, said method comprising:
i. providing bacteria, a virus, algae, mildew, or mold to be reduced in numbers; ii. treating said bacteria, virus, algae, mildew or mold using a composition of matter having the average general for... | Compositions of matter that have antimicrobial properties and adhesion properties and are highly dispersible in aqueous solutions. The presence of a large number of silanols on the molecules of this invention creates a solubility or disperseability of these molecules in aqueous solutions that is not obtainable from pri... | 1,600 |
57 | 57 | 14,126,928 | 1,644 | The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a nitrogen mustard for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia. | 1. A synergistic combination of an antibody specific for CD19 comprising an antibody that cross-competes with an antibody comprising an HCDR1 region of sequence SYVMH (SEQ ID NO:1), an HCDR2 region of sequence NPYNDG (SEQ ID NO: 2), an HCDR3 region of sequence GTYYYGTRVFDY (SEQ ID NO: 3), an LCDR1 region of sequence RS... | The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a nitrogen mustard for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and/or acute lymphoblastic leukemia.1. A synergistic combination of an antibody specific for CD19 comprising an antibody that cross-comp... | 1,600 |
58 | 58 | 14,124,096 | 1,612 | The invention relates to cosmetic and dermatological photoprotective preparations comprising, in addition to UV filter substances, polyglyceryl-10 stearate as emulsifier. Said preparations have improved water resistance. | 1.-13. (canceled) 14. A water-resistant cosmetic or dermatological photoprotective preparation, wherein the preparation comprises one or more UV filter substances, less than 6% by weight of polyglyceryl-10 stearate, based on a total weight of the preparation, and comprises no lecithins, O/W emulsion preparations of the... | The invention relates to cosmetic and dermatological photoprotective preparations comprising, in addition to UV filter substances, polyglyceryl-10 stearate as emulsifier. Said preparations have improved water resistance.1.-13. (canceled) 14. A water-resistant cosmetic or dermatological photoprotective preparation, wher... | 1,600 |
59 | 59 | 15,144,622 | 1,615 | Liquid lipstick compositions capable of forming a multilayer structure after application to lips are provided, as well as methods of applying such compositions to lips. | 1. A liquid lipstick composition capable of forming a multilayer structure after application to lips,
wherein the liquid lipstick composition comprises at east two immiscible components prior to application, wherein the at least two immiscible components are: Component A which comprises 15% to 60% by weight with respec... | Liquid lipstick compositions capable of forming a multilayer structure after application to lips are provided, as well as methods of applying such compositions to lips.1. A liquid lipstick composition capable of forming a multilayer structure after application to lips,
wherein the liquid lipstick composition comprises ... | 1,600 |
60 | 60 | 13,900,323 | 1,628 | Compositions and methods for treating ear infections are disclosed. More specifically, these methods may refer to treatment of internal otitis using an otic composition, such as otic gel for animals and humans. Poloxamer otic gel may be in liquid state at room temperature and may change to gel at about temperature (64°... | 1. An otic pharmaceutical composition, comprising:
a) an active pharmaceutical ingredient (API); and b) a vehicle, wherein the vehicle is poloxamer 407; wherein the composition is a gel. 2. The otic pharmaceutical composition of claim 1, wherein the composition comprises 20% to 30% poloxamer 407. 3. The otic pharmaceut... | Compositions and methods for treating ear infections are disclosed. More specifically, these methods may refer to treatment of internal otitis using an otic composition, such as otic gel for animals and humans. Poloxamer otic gel may be in liquid state at room temperature and may change to gel at about temperature (64°... | 1,600 |
61 | 61 | 12,441,762 | 1,612 | A galenical form for the administration transmucously of at least one active ingredient, characterized in that the active ingredient is in a stable and complete dissolved state in a hydroalcoholic solution that includes at least 20% by mass of alcohol so as to allow rapid absorption of the active ingredient through the... | 1. Galenical form for the administration by transmucous means of at least one active ingredient, characterized in that said active ingredient is in a stable and complete dissolved state in a hydroalcoholic solution that comprises at least 20% by mass of alcohol so as to allow rapid absorption of said active ingredient ... | A galenical form for the administration transmucously of at least one active ingredient, characterized in that the active ingredient is in a stable and complete dissolved state in a hydroalcoholic solution that includes at least 20% by mass of alcohol so as to allow rapid absorption of the active ingredient through the... | 1,600 |
62 | 62 | 13,379,468 | 1,628 | A pharmaceutical composition for treatment of a pathological condition in a patient comprises, as a first component, a manganese complex of Formula I( ), and, as a second component, a non-manganese complex compound of Formula (I), optionally together with one or more physiologically acceptable carriers and/or excipient... | 1. A pharmaceutical composition for treatment of a pathological condition in a patient, comprising, as a first component, a manganese complex of Formula I, and, as a second component, a non-manganese complex compound of Formula I, optionally together with one or more physiologically acceptable carriers and/or excipient... | A pharmaceutical composition for treatment of a pathological condition in a patient comprises, as a first component, a manganese complex of Formula I( ), and, as a second component, a non-manganese complex compound of Formula (I), optionally together with one or more physiologically acceptable carriers and/or excipient... | 1,600 |
63 | 63 | 14,542,486 | 1,628 | The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) for treatment of pulmonary conditions (e.g. asthma). The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treat... | 1. A high penetration prodrug for treatment of a pulmonary condition comprising
a) a functional unit; b) a linker c) a transportational unit; the functional unit being covalently linked to the transportational unit via the linker; the functional unit comprising a moiety of a parent drug or of a related compound of the ... | The invention provides compositions of novel high penetration compositions (HPC) or high penetration prodrugs (HPP) for treatment of pulmonary conditions (e.g. asthma). The HPCs/HPPs are capable of being converted to parent active drugs or drug metabolites after crossing the biological barrier and thus can render treat... | 1,600 |
64 | 64 | 15,533,777 | 1,617 | Cosmetic oil-in-water emulsions that can provide a hydrophobic film to protect from excessive hydration are disclosed. In some aspects, a cosmetic oil-in-water emulsion can include water at a concentration of at least about 70% by total weight of the cosmetic oil-in-water emulsion, a plurality of water-in-oil emulsifie... | 1. A cosmetic oil-in-water emulsion comprising:
water at a concentration of at least about 70% by total weight of the cosmetic oil-in-water emulsion; a plurality of water-in-oil emulsifiers; a base oil; the base oil having a wVTR of about 1.0 to 30 g/m2/hr and being at a concentration of no more than about 15% by total... | Cosmetic oil-in-water emulsions that can provide a hydrophobic film to protect from excessive hydration are disclosed. In some aspects, a cosmetic oil-in-water emulsion can include water at a concentration of at least about 70% by total weight of the cosmetic oil-in-water emulsion, a plurality of water-in-oil emulsifie... | 1,600 |
65 | 65 | 14,439,471 | 1,629 | Methods for treatment of cancer selected from lung cancer, ovarian cancer, squamous cell carcinoma, pancreas exocrine cancer, malignant melanoma, gastric cancer, esophageal cancer, a metastases thereof, and leukemia, in a human or non-human body, comprise administrating to the body a cancer-inhibiting amount of a first... | 1. A method for treatment of cancer selected from lung cancer, ovarian cancer, squamous cell carcinoma, pancreas exocrine cancer, malignant melanoma, gastric cancer, esophageal cancer, a metastases thereof, and leukemia, in a human or non-human body, said method comprising administrating to said body a cancer-inhibitin... | Methods for treatment of cancer selected from lung cancer, ovarian cancer, squamous cell carcinoma, pancreas exocrine cancer, malignant melanoma, gastric cancer, esophageal cancer, a metastases thereof, and leukemia, in a human or non-human body, comprise administrating to the body a cancer-inhibiting amount of a first... | 1,600 |
66 | 66 | 14,131,159 | 1,619 | The invention disclosed herein includes nanocomplexes that are designed include enzymes that have complementary functional attributes and methods for using these nanocomplexes. Illustrative examples include nanocomplexes that comprise both an alcohol oxidase enzyme as well as a catalase enzyme. These nanocomplexes can ... | 1. A method of decreasing the concentration of ethanol in an individual comprising the steps of:
(a) administering a multiple-enzyme nanocomplex system to the individual, wherein the multiple-enzyme nanocomplex system comprises:
an alcohol oxidase enzyme that generates hydrogen peroxide in a first enzymatic reaction wi... | The invention disclosed herein includes nanocomplexes that are designed include enzymes that have complementary functional attributes and methods for using these nanocomplexes. Illustrative examples include nanocomplexes that comprise both an alcohol oxidase enzyme as well as a catalase enzyme. These nanocomplexes can ... | 1,600 |
67 | 67 | 13,911,961 | 1,619 | The present invention is directed to pharmaceutical compositions and dosage forms comprising TPR beads, wherein said TPR beads comprise a solid dispersion of at least one active pharmaceutical ingredient in at least one solubility-enhancing polymer, and a TPR coating comprising a water insoluble polymer and an enteric ... | 1. A pharmaceutical composition comprising TPR beads, wherein said TPR beads comprise:
a solid dispersion of at least one active pharmaceutical ingredient in at least one solubility-enhancing polymer; and a TPR coating comprising a water insoluble polymer and an enteric polymer; wherein the active pharmaceutical ingred... | The present invention is directed to pharmaceutical compositions and dosage forms comprising TPR beads, wherein said TPR beads comprise a solid dispersion of at least one active pharmaceutical ingredient in at least one solubility-enhancing polymer, and a TPR coating comprising a water insoluble polymer and an enteric ... | 1,600 |
68 | 68 | 14,861,009 | 1,617 | A method of preventing degeneration of photoreceptor cells in an eye of a mammalian subject includes the step of administering pharmaceutical composition comprising a sulindac agent to the eye of the subject. | 1. A method of preventing degeneration of photoreceptor cells and retinal pigment epithelial cells in an eye of a mammalian subject having or at high risk of developing retinal disease, the method comprising the step of administering an ophthalmically-acceptable pharmaceutical composition comprising a sulindac agent to... | A method of preventing degeneration of photoreceptor cells in an eye of a mammalian subject includes the step of administering pharmaceutical composition comprising a sulindac agent to the eye of the subject.1. A method of preventing degeneration of photoreceptor cells and retinal pigment epithelial cells in an eye of ... | 1,600 |
69 | 69 | 14,982,220 | 1,619 | A topically applicable chemical peel composition for home use having from about 4% to about 13%, by weight, of alpha hydroxy acid, from about 0.1% to about 2.0%, by weight, of salicylic acid, from about 0.1% to about 2.0%, by weight, of phenylethyl resorcinol and balance essentially dermatologically acceptable liquid s... | 1. A topically applicable chemical peel composition comprising:
from about 8% to about 12%, by weight, of alpha hydroxy acid;
from about 0.1% to about 2.0%, by weight, of salicylic acid;
from about 0.1% to about 2.0%, by weight, of phenylethyl resorcinol; balance essentially dermatologically acceptable liquid solvent.... | A topically applicable chemical peel composition for home use having from about 4% to about 13%, by weight, of alpha hydroxy acid, from about 0.1% to about 2.0%, by weight, of salicylic acid, from about 0.1% to about 2.0%, by weight, of phenylethyl resorcinol and balance essentially dermatologically acceptable liquid s... | 1,600 |
70 | 70 | 13,583,754 | 1,631 | In many situations, particularly in forensic science, there is a need to consider one piece of evidence against one or more other pieces of evidence. For instance, it may be desirable to compare a sample collected from a crime scene with a sample collected from a person, with a view to linking the two by comparing the ... | 1. A method of comparing a first sample result set with a second sample result set, the method comprising:
a) providing information for the first result set on the one or more identities detected for a variable characteristic of DNA; b) providing information for the second result set on the one or more identities detec... | In many situations, particularly in forensic science, there is a need to consider one piece of evidence against one or more other pieces of evidence. For instance, it may be desirable to compare a sample collected from a crime scene with a sample collected from a person, with a view to linking the two by comparing the ... | 1,600 |
71 | 71 | 12,356,982 | 1,632 | The present invention provides methods and devices for isolating cells from a subject by circulating the subject's body fluid over an affinity moeity coupled matrix to isolate isolate cells from a subject either ex vivo or in vivo. One aspect of the invention is directed to connecting a subject to a system capable of c... | 1. A method of isolating cells from a subject, comprising:
connecting a subject to a system capable of circulating body fluid therethrough, wherein the system comprises an affinity moiety coupled matrix; passing the body fluid through the affinity moiety coupled matrix, such that the body fluid is returned to the subje... | The present invention provides methods and devices for isolating cells from a subject by circulating the subject's body fluid over an affinity moeity coupled matrix to isolate isolate cells from a subject either ex vivo or in vivo. One aspect of the invention is directed to connecting a subject to a system capable of c... | 1,600 |
72 | 72 | 15,117,719 | 1,619 | Surprisingly, it has been found in accordance with the invention that, by adding guanidinoacetic acid, creatine and/or their salts to the feed of parent animals, the hatching rate of eggs can be increased, the embryo mortality can be reduced and the chicks' growth and feed conversion can be increased. | 1-15. (canceled) 16. A method for increasing the hatching rate in eggs, and/or for reducing embryo mortality, and/or for improving chick growth, and/or for improving the chicks' feed conversion, comprising feeding parent animals a feed which comprises guanidinoacetic acid; creatine; salts of these compounds; and mixtur... | Surprisingly, it has been found in accordance with the invention that, by adding guanidinoacetic acid, creatine and/or their salts to the feed of parent animals, the hatching rate of eggs can be increased, the embryo mortality can be reduced and the chicks' growth and feed conversion can be increased.1-15. (canceled) 1... | 1,600 |
73 | 73 | 14,443,255 | 1,617 | The invention relates to a composition for dip treatment of plant roots comprising a substance of interest and a branched polysaccharide, in particular xanthan gum. | 1. A composition intended for dip treatment of a plant, comprising a branched polysaccharide and also a substance of interest. 2. The composition as claimed in claim 1, characterized in that said substance of interest is an endomycorrhizal fungus. 3. The composition as claimed in claim 2, characterized in that said end... | The invention relates to a composition for dip treatment of plant roots comprising a substance of interest and a branched polysaccharide, in particular xanthan gum.1. A composition intended for dip treatment of a plant, comprising a branched polysaccharide and also a substance of interest. 2. The composition as claimed... | 1,600 |
74 | 74 | 13,562,879 | 1,618 | Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing ... | 1.-80. (canceled) 81. A method of imaging a site, diagnosing a disease, or treating a disease within a subject comprising:
(a) obtaining an ethylenedicysteine-glucosamine (EC-DG) metal ion-labeled-chelator targeting ligand conjugate, the conjugate being between about 90% and about 99.9% pure; and (b) administering to t... | Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing ... | 1,600 |
75 | 75 | 14,396,202 | 1,655 | The present invention relates to compositions comprising substances of natural origin for use in the treatment or preventing the onset or the aggravation of diabetic foot ulcers. | 1. A composition comprising beeswax, an extract of Hypericum, an extract of red grape vine, an extract of horse chestnut, an extract of Centella, an extract of butcher's broom, and an extract of Aloe for use in treating or preventing onset or aggravation of diabetic foot ulcers. 2. The composition according to claim 1,... | The present invention relates to compositions comprising substances of natural origin for use in the treatment or preventing the onset or the aggravation of diabetic foot ulcers.1. A composition comprising beeswax, an extract of Hypericum, an extract of red grape vine, an extract of horse chestnut, an extract of Centel... | 1,600 |
76 | 76 | 13,836,139 | 1,631 | The present invention relates to systems and methods for the characterization of biological material within a sample or isolate. The characterization may utilize probabilistic methods that compare sequencing information from fragment reads to sequencing information of reference genomic databases and/or trait-specific d... | 1. A method of characterizing organisms based on sequence information derived from a sample containing genetic material from the organisms, the method comprising:
(a) receiving, by a processing unit including a processor and memory, the sequence information derived from the sample, wherein the sequence information incl... | The present invention relates to systems and methods for the characterization of biological material within a sample or isolate. The characterization may utilize probabilistic methods that compare sequencing information from fragment reads to sequencing information of reference genomic databases and/or trait-specific d... | 1,600 |
77 | 77 | 12,592,700 | 1,617 | An antimicrobial agent to kill microorganisms by enhancing the concentration of metal ions through use of compound containing a hydantoin ring in the presence of a liquid. The method includes the step of to enhancing the effectiveness of the biocidal component to lessen the need for a supplemental biocide wherein the a... | 1. An antimicrobial agent for use in killing microorganisms comprising:
a microorganism killing material comprising a source of biocidal metal ions wherein the level of available biocidal metal ions to kill microorganisms is limited by the presence of a liquid; and a compound containing a hydantoin ring, wherein the co... | An antimicrobial agent to kill microorganisms by enhancing the concentration of metal ions through use of compound containing a hydantoin ring in the presence of a liquid. The method includes the step of to enhancing the effectiveness of the biocidal component to lessen the need for a supplemental biocide wherein the a... | 1,600 |
78 | 78 | 14,791,553 | 1,616 | Stable aerosol solution formulations comprising glycopyrronium bromide are useful for administration to patients with COPD and other respiratory conditions. | 1. A pharmaceutical composition, comprising glycopyrronium bromide dissolved in an HFA propellant and a co-solvent, wherein said composition comprises an amount of hydrochloric acid equivalent to 0.005 to 1.0 μg/μl of 1M hydrochloric acid. 2. A composition according to claim 1, wherein said composition comprises an amo... | Stable aerosol solution formulations comprising glycopyrronium bromide are useful for administration to patients with COPD and other respiratory conditions.1. A pharmaceutical composition, comprising glycopyrronium bromide dissolved in an HFA propellant and a co-solvent, wherein said composition comprises an amount of ... | 1,600 |
79 | 79 | 14,671,322 | 1,644 | Compositions that include at least one isolated, class I HLA trimolecular complex that includes a peptide ligand unique to M. tuberculosis -infected cells are disclosed. Isolated compositions that include the three components of the trimolecular complex and/or a polynucleotide encoding one or more of the three compone... | 1. A composition, comprising at least one of:
(a) an isolated class I HLA trimolecular complex formed in vitro, the trimolecular complex comprising a soluble, truncated HLA-E heavy chain, beta-2-microglobulin, and a peptide comprising SEQ ID NO:1, and wherein the soluble, truncated HLA-E heavy chain does not contain th... | Compositions that include at least one isolated, class I HLA trimolecular complex that includes a peptide ligand unique to M. tuberculosis -infected cells are disclosed. Isolated compositions that include the three components of the trimolecular complex and/or a polynucleotide encoding one or more of the three compone... | 1,600 |
80 | 80 | 15,583,697 | 1,616 | Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration. | 1-24. (canceled) 25. A method of treating inflammation or a related disorder, comprising the administration, to a patient in need thereof, a delayed-release oral pharmaceutical dosage form comprising MGBG. 26. The method as recited in claim 25, wherein said delayed release oral pharmaceutical dosage form is an enterica... | Disclosed herein are controlled-release oral pharmaceutical dosage forms comprising MGBG, and their application for the improved treatment of diseases with reduced side effects and/or longer time at maximum concentration.1-24. (canceled) 25. A method of treating inflammation or a related disorder, comprising the admini... | 1,600 |
81 | 81 | 14,639,043 | 1,616 | Light protecting compositions contain at least one polysiloxane-based UV filter. The composition has an increased ratio of the sunprotecting factor to the total UV filter amount. This is achieved by the combination with at least one UV filter which chromophore contains appropriate bulky (sterically demanding) substitue... | 1. A light protecting composition comprising:
a) polysilicone-15 (Parsol SLX), b) at least one additional UV filter selected from the group consisting of 2-(4-diethylamino-2-hydroxy-benzoyl)-benzoic acid hexylester, 4-methyl benzylidene camphor, and methylene bis-benzotriazol bis-benzotriazo tetramethylbutylphenol, c) ... | Light protecting compositions contain at least one polysiloxane-based UV filter. The composition has an increased ratio of the sunprotecting factor to the total UV filter amount. This is achieved by the combination with at least one UV filter which chromophore contains appropriate bulky (sterically demanding) substitue... | 1,600 |
82 | 82 | 14,504,925 | 1,627 | The present disclosure provides a method for the treatment of Parkinson's disease comprising simultaneously or sequentially administering to a patient in need of treatment of Parkinson's disease a dosage form comprising
(i) levodopa in an amount ranging from 50 mg to 300 mg, (ii) carbidopa in an amount rangi... | 1. A method for the treatment of Parkinson's disease comprising simultaneously or sequentially orally administering to a patient in need of treatment of Parkinson's disease
(i) levodopa in an amount ranging from 75 mg to 175 mg, (ii) carbidopa in an amount ranging from 65 mg to 105 mg, and (iii) entacapone in an amount... | The present disclosure provides a method for the treatment of Parkinson's disease comprising simultaneously or sequentially administering to a patient in need of treatment of Parkinson's disease a dosage form comprising
(i) levodopa in an amount ranging from 50 mg to 300 mg, (ii) carbidopa in an amount rangi... | 1,600 |
83 | 83 | 14,236,152 | 1,653 | As a simple and convenient method for promoting the proliferation of algae, a method for cultivating the algae while conducting a procedure S 1 for irradiating a red illuminative light to the algae and a procedure S 2 for irradiating a blue illuminative light to the algae separately and independently of each other wi... | 1. An algae cultivation method for promoting the proliferation of algae by conducting a procedure for irradiating a red illuminative light to the algae and a procedure for irradiating a blue illuminative light to the algae separately and independently of each other within a certain time period. 2. The algae cultivation... | As a simple and convenient method for promoting the proliferation of algae, a method for cultivating the algae while conducting a procedure S 1 for irradiating a red illuminative light to the algae and a procedure S 2 for irradiating a blue illuminative light to the algae separately and independently of each other wi... | 1,600 |
84 | 84 | 14,749,126 | 1,611 | The present invention provides a hydroxyalkyl cellulose having a viscosity of 1.10 mPa·s to 1.95 mPa·s in a 2%-concentration aqueous solution at 20° C., and a solid formulation containing the hydroxyalkyl cellulose. | 1-4. (canceled) 5. Coated particles comprising:
core particles; and a coating layer that covers the core particles, wherein the coating layer contains a hydroxyalkyl cellulose that has a viscosity of 1.10 mPa·s to 1.95 mPa·s in a 2%-concentration aqueous solution at 20° C. 6. The coated particles according to claim 5, ... | The present invention provides a hydroxyalkyl cellulose having a viscosity of 1.10 mPa·s to 1.95 mPa·s in a 2%-concentration aqueous solution at 20° C., and a solid formulation containing the hydroxyalkyl cellulose.1-4. (canceled) 5. Coated particles comprising:
core particles; and a coating layer that covers the core ... | 1,600 |
85 | 85 | 15,115,704 | 1,617 | What is proposed is aqueous surfactant compositions comprising
one or more alpha-sulfo fatty acid disalts (A) of the general formula (I),
R 1 CH(SO 3 M 1 )COOM 2 (I)
in which the radical R 1 is a linear or branched alkyl or alkenyl radical with 6 to 16 carbon atoms and the radicals M 1 and M 2... | 1. An aqueous surfactant composition comprising
one or more alpha-sulfo fatty acid disalt (A) of general formula (I),
R1CH(SO3M1)COOM2 (I)
in which radical R1 is a linear or branched alkyl or alkenyl radical with 6 to 16 carbon atoms and the radicals M1 and M2, independently of one another, are selected from the ... | What is proposed is aqueous surfactant compositions comprising
one or more alpha-sulfo fatty acid disalts (A) of the general formula (I),
R 1 CH(SO 3 M 1 )COOM 2 (I)
in which the radical R 1 is a linear or branched alkyl or alkenyl radical with 6 to 16 carbon atoms and the radicals M 1 and M 2... | 1,600 |
86 | 86 | 14,070,075 | 1,653 | The invention is generally directed to reducing inflammation by means of cells that secrete factors that reduce leukocyte extravasation. Specifically, the invention is directed to methods using cells that secrete factors that downregulate the expression of cellular adhesion molecules in leukocytes. Downregulating expre... | 1. (canceled) 2. A method to treat inflammation in a subject, said method comprising assessing cells in a preparation of cells for a desired potency for one or more of the following: (1) reduce leukocyte extravasation, (2) reduce leukocyte adhesion to vascular endothelium or to isolated endothelial cells, (3) reduce Fu... | The invention is generally directed to reducing inflammation by means of cells that secrete factors that reduce leukocyte extravasation. Specifically, the invention is directed to methods using cells that secrete factors that downregulate the expression of cellular adhesion molecules in leukocytes. Downregulating expre... | 1,600 |
87 | 87 | 14,663,470 | 1,643 | Twenty-one PSGR-derived peptides predicted by an immuno-informatics approach based on the HLA-A2 binding motif were examined for their ability to induce peptide-specific T cell responses in peripheral blood mononuclear cells (PBMCs) obtained from either HLA-A2+ healthy donors or HLA-A2+ prostate cancer patients. The re... | 1. A method of treating prostate cancer comprising administering to a patient in need thereof an effective amount of a peptide selected from the group consisting of PSGR3, PSGR4 and PSGR4, or combinations of two or more of the three peptides. 2. The method of claim 1 wherein the peptides are co-administered. 3. The met... | Twenty-one PSGR-derived peptides predicted by an immuno-informatics approach based on the HLA-A2 binding motif were examined for their ability to induce peptide-specific T cell responses in peripheral blood mononuclear cells (PBMCs) obtained from either HLA-A2+ healthy donors or HLA-A2+ prostate cancer patients. The re... | 1,600 |
88 | 88 | 14,358,839 | 1,653 | The present invention relates to a method for detecting the presence of expanded-spectrum β-lactamase (β-lactamase hydrolyzing expanded-spectrum cephalosporin)-producing bacteria in a sample, said method comprising the steps of: a) performing cell lysis on a test sample in order to obtain an enzymatic suspension; b) re... | 1. A method for detecting the presence of expanded-spectrum β-lactamase-producing bacteria in a sample, said method comprising the steps of:
a) performing cell lysis on a test sample in order to obtain an enzymatic suspension;
b) reacting a fraction of the enzymatic suspension obtained in step a) with a reagent kit, sa... | The present invention relates to a method for detecting the presence of expanded-spectrum β-lactamase (β-lactamase hydrolyzing expanded-spectrum cephalosporin)-producing bacteria in a sample, said method comprising the steps of: a) performing cell lysis on a test sample in order to obtain an enzymatic suspension; b) re... | 1,600 |
89 | 89 | 15,265,237 | 1,617 | An effervescent composition is provided which contains a phase-stable oil-in-water emulsion comprising a discontinuous oil phase homogenously distributed within continuous water phase, wherein the discontinuous oil phase comprises a UV-absorbing compound; and from about 20% to about 30% by weight of the composition of ... | 1. A composition, comprising:
a phase-stable oil-in-water emulsion comprising a discontinuous oil phase homogenously distributed within continuous a water phase, wherein said discontinuous oil phase comprises a UV-absorbing compound; and from about 20% to about 30% by weight of said composition of a combination of at l... | An effervescent composition is provided which contains a phase-stable oil-in-water emulsion comprising a discontinuous oil phase homogenously distributed within continuous water phase, wherein the discontinuous oil phase comprises a UV-absorbing compound; and from about 20% to about 30% by weight of the composition of ... | 1,600 |
90 | 90 | 13,513,164 | 1,634 | This disclosure is directed to, inter alia, methods and compositions for hybridizing at least one molecule to a target. The invention may, for example, eliminate the use of, or reduce the dependence on formamide in hybridization. Compositions for use in the invention include an aqueous composition comprising at least o... | 1. A method of hybridizing nucleic acid sequences without a denaturation step, or using a low-temperature denaturation step comprising:
providing a first nucleic acid sequence, providing a second nucleic acid sequence, providing a hybridization composition comprising an effective amount of at least one polar aprotic so... | This disclosure is directed to, inter alia, methods and compositions for hybridizing at least one molecule to a target. The invention may, for example, eliminate the use of, or reduce the dependence on formamide in hybridization. Compositions for use in the invention include an aqueous composition comprising at least o... | 1,600 |
91 | 91 | 14,420,911 | 1,623 | In a process for preparing an esterified cellulose ether a cellulose ether is esterified with (i) an aliphatic monocarboxylic acid anhydride or (ii) a dicarboxylic acid anhydride or (iii) a combination of an aliphatic monocarboxylic acid anhydride and a dicarboxylic acid anhydride in the presence of an alkali metal car... | 1. A process for preparing an esterified cellulose ether wherein a cellulose ether is esterified with (i) an aliphatic monocarboxylic acid anhydride or (ii) a dicarboxylic acid anhydride or (iii) a combination of an aliphatic monocarboxylic acid anhydride and a dicarboxylic acid anhydride in the presence of an alkali m... | In a process for preparing an esterified cellulose ether a cellulose ether is esterified with (i) an aliphatic monocarboxylic acid anhydride or (ii) a dicarboxylic acid anhydride or (iii) a combination of an aliphatic monocarboxylic acid anhydride and a dicarboxylic acid anhydride in the presence of an alkali metal car... | 1,600 |
92 | 92 | 13,157,036 | 1,615 | The presently disclosed subject matter relates to nitric oxide-releasing particles for delivering nitric oxide, and their use in biomedical and pharmaceutical applications. | 1. A nitric oxide-releasing particle, the nitric oxide-releasing particle comprising a nitric oxide donor and having a total releasable nitric oxide storage of at least 1.2 μmol of NO per milligram of the nitric oxide releasing particle. 2. The nitric oxide releasing particle of claim 1, wherein the nitric oxide-releas... | The presently disclosed subject matter relates to nitric oxide-releasing particles for delivering nitric oxide, and their use in biomedical and pharmaceutical applications.1. A nitric oxide-releasing particle, the nitric oxide-releasing particle comprising a nitric oxide donor and having a total releasable nitric oxide... | 1,600 |
93 | 93 | 13,821,787 | 1,627 | The invention provides a compound of formula (I): or a salt thereof, wherein R 1 -R 5 have any of the values described in the specification, as well as compositions comprising a compound of formula (I). The compounds are useful as RNA polymerase inhibitors and antibacterial agents. | 1. A compound of formula I:
wherein:
R1 is one of aryl and heteroaryl, and optionally is substituted with one or more groups independently selected from halo, hydroxy, carboxy, cyano, nitro, trifluoromethyl, trifluoromethoxy, (C1-C6)alkyl, (C2-C6)alkenyl, (C1-C6)alkoxy, (C1-C6)alkoxycarbonyl, (C1-C6)alkanoylo... | The invention provides a compound of formula (I): or a salt thereof, wherein R 1 -R 5 have any of the values described in the specification, as well as compositions comprising a compound of formula (I). The compounds are useful as RNA polymerase inhibitors and antibacterial agents.1. A compound of formula I:
... | 1,600 |
94 | 94 | 14,877,208 | 1,627 | Described herein are abuse deterrent controlled release oral pharmaceutical compositions comprising and methods for making the same. In particular, an abuse deterrent controlled release oral pharmaceutical composition comprising a soft capsule and an abuse deterrent controlled release matrix comprising an active pharma... | 1. An abuse deterrent oral pharmaceutical composition comprising a tamper resistant controlled release matrix comprising:
(a) at least one lipid or lipophilic vehicle; (b) at least one organogelator; (c) at least one hydrophilic polymer; (d) at least one hydrophilic vehicle; and (e) at least one active pharmaceutical i... | Described herein are abuse deterrent controlled release oral pharmaceutical compositions comprising and methods for making the same. In particular, an abuse deterrent controlled release oral pharmaceutical composition comprising a soft capsule and an abuse deterrent controlled release matrix comprising an active pharma... | 1,600 |
95 | 95 | 14,679,233 | 1,627 | Described herein are abuse deterrent controlled release oral pharmaceutical compositions comprising and methods for making the same. In particular, an abuse deterrent controlled release oral pharmaceutical composition comprising a soft capsule and an abuse deterrent controlled release matrix comprising an active pharma... | 1. An abuse deterrent oral pharmaceutical composition comprising a tamper resistant controlled release matrix comprising:
(a) at least one lipid or lipophilic vehicle; (b) at least one organogelator; (c) at least one hydrophilic polymer; (d) at least one hydrophilic vehicle; and (e) at least one active pharmaceutical i... | Described herein are abuse deterrent controlled release oral pharmaceutical compositions comprising and methods for making the same. In particular, an abuse deterrent controlled release oral pharmaceutical composition comprising a soft capsule and an abuse deterrent controlled release matrix comprising an active pharma... | 1,600 |
96 | 96 | 14,356,846 | 1,631 | Methods and systems for filtering variants in data sets comprising genomic information are provided herein. | 1. A biological context filter wherein the biological context filter:
(a) is configured to receive a data set comprising variants wherein the data set comprises variant data from one or more samples from one or more individuals, (b) is in communication with a database of biological information, and (c) is capable of tr... | Methods and systems for filtering variants in data sets comprising genomic information are provided herein.1. A biological context filter wherein the biological context filter:
(a) is configured to receive a data set comprising variants wherein the data set comprises variant data from one or more samples from one or mo... | 1,600 |
97 | 97 | 14,333,533 | 1,624 | This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy. | 1. Method for the treatment of cancerous cell growth mediated by raf kinase comprising administering a compound of Formula I:
A-D-B (I)
or a pharmaceutically acceptable salt thereof, wherein
D is —NH—C(O)—NH—,
A is a substituted moiety of up to 40 carbon atoms of the formula: -L-(M-L1)q, where L is a 5 or 6 membere... | This invention relates to the use of a group of aryl ureas in treating raf mediated diseases, and pharmaceutical compositions for use in such therapy.1. Method for the treatment of cancerous cell growth mediated by raf kinase comprising administering a compound of Formula I:
A-D-B (I)
or a pharmaceutically acceptab... | 1,600 |
98 | 98 | 15,307,782 | 1,612 | An oral care composition comprising (a) a silica abrasive having an average particle size of no greater than the diameter of a dentin tubule, or, alternatively 8 microns or less; (b) zinc citrate, (c) a bioadhesive agent, and (d) an anticalculus agent. The oral care composition can reduce or inhibit biofilm formation a... | 1. An oral care composition comprising
(a) a silica abrasive having an average particle size of 8 microns or less, 1.5-6 microns, 2.7-4 microns or 3.5 microns; (b) zinc citrate, (c) a bioadhesive agent, and (d) an anticalculus agent. 2. The oral care composition of claim 1, in the form of a dentifrice wherein
the silic... | An oral care composition comprising (a) a silica abrasive having an average particle size of no greater than the diameter of a dentin tubule, or, alternatively 8 microns or less; (b) zinc citrate, (c) a bioadhesive agent, and (d) an anticalculus agent. The oral care composition can reduce or inhibit biofilm formation a... | 1,600 |
99 | 99 | 11,482,761 | 1,616 | Photoprotective cosmetic compositions having at least reduced shine, stickiness, whitening and/or fluffiness and/or enhanced SPF contain an effective amount of at least one UV radiation filtering agent, at least one aqueous phase and at least one apolar wax having a melting point greater than or equal to 30° C. and a f... | 1. A topically applicable photoprotective cosmetic composition comprising an effective amount of at least one UV radiation filtering agent, at least one aqueous phase and at least one apolar wax having a melting point greater than or equal to 30° C. and a fusion enthalpy of less than 250 J/g, formulated into a topicall... | Photoprotective cosmetic compositions having at least reduced shine, stickiness, whitening and/or fluffiness and/or enhanced SPF contain an effective amount of at least one UV radiation filtering agent, at least one aqueous phase and at least one apolar wax having a melting point greater than or equal to 30° C. and a f... | 1,600 |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.